AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$GRAL

Partridge Andrew John sold $1.2M of GRAL

Partridge Andrew John (Chief Growth Officer) sold 7,873 shares of GRAIL, Inc. (GRAL) at $146.39 ($1.15M total) on 2026-10-05.

Original reporting
SEC EDGAR · Partridge Andrew John
Published Oct 7, 2026, 10:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRAL
Bearish
medium confidence
Mentioned
$GRAL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRALBearishLow
01

Why it matters

The filing provides fresh data on insider activity, useful for short‑term sentiment assessment.

02

Market read

First‑report insider sale gives traders new insight into potential stock pressure.

03

What to watch

Insider may be diversifying holdings or meeting a liquidity event unrelated to company outlook.

Relevance 6/10Novelty 7/10Timing: today

Background

SEC Form 4 filing reports an insider transaction for GRAIL, Inc.

Company-level read

Ticker impact

$GRALBearishMedium confidence
Context

Chief Growth Officer sold 7,873 shares for $1.15M on Oct 5, 2026.

Expected impact

likely pressure as market prices in the insider sell.

Evidence & confidence

A senior officer offloading $1.1M of stock can be viewed as a bearish signal, though motives may vary.

Market effects

Sector

May raise concerns about insider sentiment in the biotech sector.

Regional

US biotech investors may reassess exposure.

Global

Limited to biotech peers, no broad market effect.

Counterpoint

What could challenge this read

Sale could be driven by personal tax planning rather than lack of confidence.

Key entities

  • company
    GRAIL, Inc.

    Biotech company listed on NYSE under ticker GRAL.

  • person
    Partridge Andrew John

    Chief Growth Officer of GRAIL, the reporting insider.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRAL insider trading history →

Related articles

OCT 3
$GRALHighAI 8/10

Why GRAIL (GRAL) Is Up 8.1% And What's Next After Galleri FDA Backing

GRAIL (GRAL) shares rose 8.1% after an FDA advisory panel backed its Galleri blood test, citing strong clinical data. The test showed 99.64% specificity and 60.3% positive predictive value in detecting early-stage cancers. The company projects $348.4M revenue and $60.1M earnings by 2029, but analysts warn of reimbursement risks and high cash burn.

simplywall.st3 min
SEP 30
$GRALHighAI 8/10

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Grail's (GRAL) stock rose after an FDA advisory committee voted favorably on its Galleri test. The test, already available, needs insurer coverage for growth. FDA approval, likely following the vote, could prompt insurer evaluation. Insurers will assess cost-effectiveness and clinical utility. Grail's data shows Galleri's potential in detecting 12 deadly cancers.

aol.com2 min
SEP 30
$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

rttnews.com2 min